191 related articles for article (PubMed ID: 19423011)
1. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Kim SL; Kim EM; Cheong SJ; Lee CM; Kim DW; Jeong HJ; Lim ST; Sohn MH; Yim CY
Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
[TBL] [Abstract][Full Text] [Related]
2. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
3. Glucose-6-phosphatase Expression-Mediated [
Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
[TBL] [Abstract][Full Text] [Related]
4. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction.
Moon SH; Lee SJ; Jung KH; Quach CH; Park JW; Lee JH; Cho YS; Lee KH
J Nucl Med; 2016 Jan; 57(1):129-35. PubMed ID: 26449833
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Ihle NT; Lemos R; Schwartz D; Oh J; Halter RJ; Wipf P; Kirkpatrick L; Powis G
Mol Cancer Ther; 2009 Jan; 8(1):94-100. PubMed ID: 19139117
[TBL] [Abstract][Full Text] [Related]
7. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.
Shah YM; Morimura K; Gonzalez FJ
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G657-66. PubMed ID: 17095756
[TBL] [Abstract][Full Text] [Related]
8. Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages.
Neri T; Cordazzo C; Carmazzi Y; Petrini S; Balìa C; Stefanelli F; Amoruso A; Brunelleschi S; Breschi MC; Pedrinelli R; Paggiaro P; Celi A
Cardiovasc Res; 2012 Jun; 94(3):537-44. PubMed ID: 22425902
[TBL] [Abstract][Full Text] [Related]
9. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro.
Ogawa M; Nakamura S; Saito Y; Kosugi M; Magata Y
J Nucl Med; 2012 Jan; 53(1):55-8. PubMed ID: 22128324
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography.
Maddalena F; Lettini G; Gallicchio R; Sisinni L; Simeon V; Nardelli A; Venetucci AA; Storto G; Landriscina M
Mol Imaging; 2015; 14():490-8. PubMed ID: 26461458
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice.
Wuest M; Hamann I; Bouvet V; Glubrecht D; Marshall A; Trayner B; Soueidan OM; Krys D; Wagner M; Cheeseman C; West F; Wuest F
Mol Pharmacol; 2018 Feb; 93(2):79-89. PubMed ID: 29142019
[TBL] [Abstract][Full Text] [Related]
12. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide.
Satomi T; Ogawa M; Mori I; Ishino S; Kubo K; Magata Y; Nishimoto T
J Nucl Med; 2013 Jun; 54(6):999-1004. PubMed ID: 23670898
[TBL] [Abstract][Full Text] [Related]
13. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
14. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.
Paudyal B; Oriuchi N; Paudyal P; Higuchi T; Nakajima T; Endo K
Cancer Sci; 2008 Feb; 99(2):260-6. PubMed ID: 18271924
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
[TBL] [Abstract][Full Text] [Related]
17. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
18. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
[TBL] [Abstract][Full Text] [Related]
19. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
